<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51877">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01811030</url>
  </required_header>
  <id_info>
    <org_study_id>CYN12-PICO_SCARS_RG06</org_study_id>
    <nct_id>NCT01811030</nct_id>
  </id_info>
  <brief_title>Evaluation of the 755nm Alexandrite Laser for the Treatment of Scars</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of removing unwanted scars using a 755nm Alexandrite laser.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Photographic Evaluation of Scar Clearance</measure>
    <time_frame>up to 3 months post last treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>2D and 3D photography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>4 months post last treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Subject biopsy sampling</measure>
    <time_frame>up to 4 months post treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>histological evaluation of tissue samples pre-treatment and 3-4 months post treatment to assess safety and tolerability.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Scars</condition>
  <arm_group>
    <arm_group_label>755nm Alexandrite Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>755nm Alexandrite Laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite Laser</intervention_name>
    <description>755nm Alexandrite Laser</description>
    <arm_group_label>755nm Alexandrite Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy male or female between 18 and 85 years old.

          2. Has unwanted scars (including atrophic, hypertrophic, hyper or hypo pigmented,
             erythematous )and wishes to undergo laser treatments to remove or improve them.

          3. Is willing to consent to participate in the study.

          4. Is willing to comply with all requirements of the study including being photographed,
             following post treatment care and attending all treatment and follow up visits

        Exclusion Criteria:

          1. Is hypersensitive to light exposure.

          2. Has active localized or systemic infection.

          3. Is taking medication(s) for which sunlight is a contraindication.

          4. Has a history of squamous cell carcinoma or melanoma.

          5. Has a history of keloid scarring.

          6. Has used oral isotretinoin (AccutaneÂ®) within 12 months of initial treatment or plans
             on using during the course of the study. Note: Skin must regain its normal degree of
             moisture prior to treatment.

          7. Has a history of immunosuppression/immune deficiency disorders (including HIV
             infection or AIDS) or use of immunosuppressive medications.

          8. Is female and pregnant, has been pregnant within the last 3 months, is currently
             breast feeding or planning a pregnancy during the study period.

          9. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine.

         10. Has any other reason determined by the physician to be ineligible to participate in
             the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
